GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » Capex-to-Operating-Cash-Flow

Dermapharm Holding SE (XTER:DMP) Capex-to-Operating-Cash-Flow : 2.38 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Dermapharm Holding SE's Capital Expenditure for the three months ended in Mar. 2025 was €-10.07 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was €4.23 Mil.

Hence, Dermapharm Holding SE's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 2.38.


Dermapharm Holding SE Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Dermapharm Holding SE's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Capex-to-Operating-Cash-Flow Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.24 0.14 0.19 0.19

Dermapharm Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.50 0.11 0.17 2.38

Competitive Comparison of Dermapharm Holding SE's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Capex-to-Operating-Cash-Flow falls into.


;
;

Dermapharm Holding SE Capex-to-Operating-Cash-Flow Calculation

Dermapharm Holding SE's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-38.237) / 201.378
=0.19

Dermapharm Holding SE's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-10.074) / 4.228
=2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (XTER:DMP) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Dermapharm Holding SE Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines